Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TAVR adoption rates, clinical-trial milestones, and FDA approvals fill Edwards Lifesciences鈥� disclosures with dense medical jargon. If you鈥檝e sifted through a 300-page report just to isolate heart-valve revenue or R&D costs, you know the challenge. Stock Titan turns that complexity into clarity: our AI reads every page the moment it reaches EDGAR and surfaces the metrics cardio-device investors actually track.
Need the latest numbers? The Edwards Lifesciences quarterly earnings report 10-Q filing appears here with instant commentary on transcatheter valve growth. Wondering whether insiders are signalling confidence? Track Edwards Lifesciences insider trading Form 4 transactions and receive Edwards Lifesciences Form 4 insider transactions real-time alerts. Our coverage also delivers every Edwards Lifesciences 8-K material events explained, so product recalls or trial updates never catch you off-guard鈥攎aking Edwards Lifesciences SEC filings explained simply a reality.
The insight goes deeper. Open the Edwards Lifesciences annual report 10-K simplified to see margin shifts across Surgical Structural Heart, or review the Edwards Lifesciences proxy statement executive compensation to benchmark pay against peer med-tech firms. Jump from Edwards Lifesciences executive stock transactions Form 4 directly to our Edwards Lifesciences earnings report filing analysis with one click. Whether you manage portfolios or run cardiovascular research, understanding Edwards Lifesciences SEC documents with AI means minutes, not hours, of due diligence.
- AI-powered summaries in plain English
- AG真人官方-time alerts the second filings hit EDGAR
- Full archive of every form, from 10-K to S-8
Edwards Lifesciences (EW) Q2 2025 10-Q highlights
Net sales rose 12% YoY to $1.53 bn, driven by transcatheter valve therapies, lifting 1H revenue to $2.95 bn (+9%). Gross margin slipped 240 bp to 77.5% on mix and higher manufacturing cost, but operating income still advanced 12% to $411 m helped by $21 m of TSA income from the September 2024 Critical Care divestiture. A $47 m impairment on an unexercised acquisition option and a sharply higher tax provision ($64 m vs $20 m) cut continuing-ops net income 8% to $336 m; diluted EPS fell to $0.56 (-8%).
Discontinued operations (Critical Care & one minor product line) logged a $4 m loss vs a $1 m profit last year. Combined, GAAP net income attributable to EW declined 9% to $333 m.
Cash & balance sheet
- Operating cash flow surged 79% YoY to $571 m on working-capital improvements.
- Cash & equivalents climbed to $3.27 bn; total liquidity (cash + ST investments) is $4.06 bn.
- Total liabilities fell 4% to $2.88 bn; net cash position of ~$2.7 bn.
Capital allocation & restructuring
- Repurchased $264 m of stock (-3% share count YoY); treasury stock at cost now $6.46 bn.
- AG真人官方ignment severance reserve down to $10 m; majority of payments due 2H 25.
Key takeaways: Top-line momentum and robust cash generation underline core valve franchises, while EPS was pressured by non-recurring impairment and taxes. Post-divestiture focus on structural-heart pipeline and optionality from sizeable cash balance remain central to the investment case.
Edwards Lifesciences (EW) 鈥� Form 4 insider transaction
Company Vice President, JAPAC, Daniel J. Lippis reported the sale of 4,114 EW common shares on 07/28/2025. Trades were executed in multiple lots at prices between $79.45 and $79.47, producing a weighted-average sale price of $79.4605. Following the sale, Lippis鈥� direct beneficial ownership stands at 22,001.9103 shares. No derivative transactions were reported and no other changes in ownership were disclosed.
The filing is limited to this single transaction; it does not detail additional holdings or option grants. Form 4 timing complies with SEC rules, indicating the trade likely settled on, or shortly before, the reported date.
Edwards Lifesciences (EW) 鈥� Form 4 insider filing
Corporate Vice President Daniel J. Lippis reported a single transaction dated 07 July 2025. Using transaction code F (shares withheld to cover taxes), 333 shares of common stock were disposed of at an average price of $76.79 per share. Following the tax-related withholding, Lippis鈥� direct beneficial ownership stands at 26,115.9103 shares.
No derivative securities were reported and no other acquisitions or dispositions were disclosed. The filing notes the routine quarterly purchase activity under the company鈥檚 Employee Stock Purchase Plan, but those acquisitions are not itemised in the tables. Given the small size of the tax-related disposition (鈮�1.3 % of the insider鈥檚 holdings) and the absence of open-market sales, the transaction is unlikely to have a material impact on the company鈥檚 share supply or insider-ownership sentiment.
FAQ
What is the current stock price of Edwards Lifesciences (EW)?
What is the market cap of Edwards Lifesciences (EW)?
